Friday, August 5, 2022
OANDP-L
  • Login
No Result
View All Result
The O&P EDGE
  • PECOS
  • Magazine
    • Subscription
    • Current Issue
    • Issue Archive
    • News Archive
    • Product & Service Directory
    • Advertising Information
  • O&P Jobs
    • Find a Job
    • Post a Job
  • EDGE Advantage
  • O&P Facilities
  • Resources
    • Product & Service Directory
    • Calendar
    • Contact
    • About Us
    • O&P Library
    • The Guide
    • Custom Publications
    • Advertising Information
    • EDGE Direct
    • Amplitude Media Group
  • PECOS
  • Magazine
    • Subscription
    • Current Issue
    • Issue Archive
    • News Archive
    • Product & Service Directory
    • Advertising Information
  • O&P Jobs
    • Find a Job
    • Post a Job
  • EDGE Advantage
  • O&P Facilities
  • Resources
    • Product & Service Directory
    • Calendar
    • Contact
    • About Us
    • O&P Library
    • The Guide
    • Custom Publications
    • Advertising Information
    • EDGE Direct
    • Amplitude Media Group
No Result
View All Result
The O&P EDGE Magazine
No Result
View All Result
Home News

FDA Approves OPRA Implant System

by The O&P EDGE
December 18, 2020
in News
0
SHARES
13
VIEWS
Share on FacebookShare on Twitter

Photograph by Britta Swanson.

The US Food and Drug Administration (FDA) approved the Osseoanchored Prostheses for the Rehabilitation of Amputees (OPRA) Implant System, manufactured by Integrum AB in Mölndal, Sweden. It is the first implant system marketed in the United States for adults who have transfemoral amputations.

“Today’s approval of the OPRA Implant System expands options for prostheses for individuals who have had above-the-knee amputations and can help those who have had or may have problems with rehabilitation and have not been able to benefit from available socket prostheses,” said Capt. Raquel Peat, PhD, MP, USPHS, director of the FDA’s Center for Devices and Radiological Health’s Office of Orthopedic Devices.

The OPRA system, which is surgically anchored and integrated into the patient’s residual thigh bone to allow connection to an external prosthetic limb, has been on the market under a humanitarian device exemption since 2015. Humanitarian use devices are intended to benefit patients in the treatment or diagnosis of a disease or condition that affects or is manifested in not more than 8,000 individuals in the United States per year.

The FDA evaluated the implant’s safety and effectiveness in a clinical study of 65 participants who received the implant. Effectiveness was assessed using the Questionnaire for Persons with a Transfemoral Amputation, a patient-reported outcome measure about frequency of use, mobility, problems with the device, and the patient’s overall health. The average improvement in the prosthetic use score on a 100-point scale, was 35.1 points at two years and 39.6 points at five years compared to their reported scores with a conventional socket prosthesis.

The FDA reviewed the OPRA Implant System under the Premarket Approval (PMA) pathway. PMA is the most stringent type of device marketing application required by the FDA and is based on a the FDA’s determination that the PMA application contains sufficient valid scientific evidence to provide reasonable assurance that the device is safe and effective for its intended use.

Related posts:

  1. 1995-2018 UK OPRA Trial Data Published
  2. OPRA Users Report Better Mobility, Fewer Problems
  3. FDA Authorizes Use of Bone-Anchored Prosthesis for Transfemoral Amputations
  4. FDA Authorizes Use of Bone-Anchored Prosthesis for Above-Knee Amputations
Previous Post

High-function Prosthesis Users Inform New PLUS-M Items

Next Post

Steeper Acquires Espire Elbow

Next Post

Steeper Acquires Espire Elbow

  • VIEW CURRENT ISSUE
  • SUBSCRIBE FOR FREE

RECENT NEWS

News

NAAOP To Host Virtual Congressional Fly-in

by The O&P EDGE
July 27, 2022

The National Association for the Advancement of Orthotics and Prosthetics (NAAOP) is hosting the 2022 Virtual Congressional Fly-in on Thursday,...

Read more

Research Shows Function Improvements With Multiarticulating Hands

ROMP Hires

SPS Names New Sales Manager

Get unlimited access!

Join EDGE ADVANTAGE and unlock The O&P EDGE's vast library of archived content.
SUBSCRIBE TODAY

O&P JOBS

Central

CPO – Orthotics and Prosthetics – Full Time

Pacific

CPO

Central

Were Growing!

 

© 2021 The O&P EDGE

  • About
  • Advertise
  • Contact
  • EDGE Advantage
  • OANDP-L
  • Subscribe

CONTACT US

866-613-0257

[email protected]

201 E. 4th St
Loveland, CO 80537

The most important industry news and events delivered directly to your inbox every week.

No Result
View All Result
  • PECOS
  • MAGAZINE
    • SUBSCRIBE
    • CURRENT ISSUE
    • ISSUE ARCHIVE
    • NEWS ARCHIVE
    • PRODUCTS & SERVICES DIRECTORY
    • ADVERTISING INFORMATION
  • O&P JOBS
    • FIND A JOB
    • POST A JOB
  • EDGE ADVANTAGE
  • FACILITES
  • RESOURCES
    • PRODUCTS & SERVICES DIRECTORY
    • CALENDAR
    • CONTACT
    • ABOUT US
    • O&P LIBRARY
    • THE GUIDE
    • CUSTOM PUBLICATIONS
    • ADVERTISING
    • EDGE DIRECT
    • AMPLITUDE
  • OANDP-L
  • LOGIN

© 2021The O&P EDGE

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
The O&P EDGE Magazine
 
Required 'Candidate' login to applying this job. Click here to logout And try again
 

Login to your account

  • Forgot Password? | Sign Up

Reset Password

  • Already have an account? Login

Enter the username or e-mail you used in your profile. A password reset link will be sent to you by email.

Signup to your Account

  • By clicking checkbox, you agree to our Terms and Conditions and Privacy Policy

    Already have an account? Login

Close
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?
 

Account Activation

Before you can login, you must activate your account with the code sent to your email address. If you did not receive this email, please check your junk/spam folder. Click here to resend the activation email. If you entered an incorrect email address, you will need to re-register with the correct email address.